Back

Synergistic impact of baseline eGFR and longitudinal trajectory on clinical outcomes in pulmonary arterial hypertension

28 August 2026 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Pulmonary arterial hypertension: clinical Epidemiology, Prognosis, Outcome ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Qi Wang

Fuwai Hospital, CAMS and PUMC, Beijing (China)

4 More presentations in this session

Presentation thumbnail
A proteogenomic atlas of idiopathic pulmonary arterial hypertension reveals sex-dimorphic mechanisms and potential novel therapeutic targets
Doctor X. Lin (Beijing, CN)
Abstract Slides
Presentation thumbnail
Pulmonary artery aneurysms in pulmonary arterial hypertension: prevalence, predictors, progression and clinical impact
Doctor M. Giraldez (Madrid, ES)
Abstract Slides
Presentation thumbnail
Right ventricular remodelling in pulmonary arterial hypertension after sotatercept therapy
Mrs E. Gutierrez Ortiz (Madrid, ES)
Abstract Slides
Presentation thumbnail
Prognostic impact of the time-dependent improvements in outcome measures and right ventricle to pulmonary arterial coupling across pulmonary hypertension groups: a single-center cohort
Doctor B. Kultursay (Tunceli, TR)
Abstract Slides

Access the full session

Session thumbnail
Pulmonary arterial hypertension: clinical

The Event

Event poster

ESC Congress 2026

28 August 2026 13:15 CET
You may be interested in
thumbnail
Congress Presentation
The snaky long-term trajectory of estimated glomerular filtration rate in heart failure
29 June 2021
thumbnail
Congress Presentation
Efficacy and safety of selexipag in patients with pulmonary arterial hypertension in real-life: early results of RAMPHA study
22 May 2022
thumbnail
Congress Presentation
Impacts of RAS and renal perfusion on eGFR in hypertensive patients, independent of renal artery stenosis
1 September 2025
thumbnail
Congress Presentation
Outcomes of remote pulmonary artery hemodynamic monitoring in heart failure patients with chronic kidney disease
29 June 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources